血浆SEPT9基因甲基化监测结直肠癌术后复发转移的应用价值  

Clinical significance of the serum methylated SEPT9 gene in monitoring recurrence and metastasis after radical resection of colorectal cancer

作　　者：张姗 房春芳[1] 丁洁[2] 付波 陈双峰[2] 焉鹏[1] Shan Zhang;Chunfang Fang;Jie Ding;Bo Fu;Shuangfeng Chen;Peng Yan(Department of Gastroenterology;Department of Central Laboratory,Liaocheng People＇s Hospital,Liaocheng 252000,China)

机构地区：[1]聊城市人民医院消化内科,山东省聊城市252000 [2]聊城市人民医院中心实验室,山东省聊城市252000

出　　处：《中国肿瘤临床》2018年第15期785-788,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨血浆SEPT 9基因甲基化(mSEPT9)在结直肠癌根治术后复发监测中的应用价值。方法:回顾性分析2013年2月至2015年1月聊城市人民医院确诊并行根治性手术的结直肠癌患者214例,收集术前及随访3年中的外周血样本,应用荧光探针PCR方法检测血浆mSEPT9状态,化学发光法检测血清CEA水平,评价血浆mSEPT9用于结直肠癌手术疗效评价价值,并评估血浆mSEPT9和血清CEA单独或两者联合检测对结直肠癌复发转移的诊断效力。结果:结直肠癌患者术前血浆mSEPT9检测阳性率为70.1%,血浆mSEPT9与临床分期相关(P=0.027),与年龄和性别不相关。结直肠癌根治术后,血浆mSEPT9阳性率为8.4%,与术前相比差异具有统计学意义(P<0.001)。64例结直肠癌复发转移患者mSEPT9阳性率为78.1%,CEA阳性率为40.6%,差异具有统计学意义(P<0.001)。血浆mSEPT9联合血清CEA检测能够提高结直肠癌复发转移的阳性率(84.4%vs.78.1%,P=0.016)。结论:血浆mSEPT9可作为结直肠癌根治术疗效评价及术后随访监测的分子标志物。Objective： To evaluate the clinical value of the plasma methylated septin 9 gene（mSEPT9） in monitoring recurrence and metastasis in patients after curative resection of colorectal cancer（CRC）. Methods： From February 2013 to January 2015, a total of 214 patients who were diagnosed with CRC and received radical resection were enrolled in Liaocheng People＇s Hospital. All of the patients were followed up for three years after surgery. Plasma mSEPT9 levels were preoperatively and postoperatively detected using the polymerase chain reaction（PCR） assay. Serum carcinoembryonic antigen（CEA） levels were examined using an electrochemiluminescence immunoassay. Results： The positivity rate of plasma mSEPT9 in preoperative CRC patients was 70.1%, and the positivity rates increased with increasing clinical tumor-node-metastasis stage（P=0.027）. No associations were found between the positivity rates of plasma mSEPT9 and the age or gender of CRC patients（P0.05）. After curatively intended surgery for CRC, the positivity rate of plasma mSEPT9 decreased to 8.4%（P0.001）. In 64 recurrent and metastasis CRC cases, the positivity rate of plasma mSEPT9 was 78.1%, while the serum CEA positivity rate was 40.6%（P0.001）. Compared with mSEPT9 independently, the positivity rate could be improved for CRC recurrences and metastasis using the combined detection of plasma mSEPT9 and serum CEA（81.3% vs. 78.1%; P=0.756）. Conclusions： Plasma mSEPT9 is a sensitive biomarker for monitoring CRC recurrence and metastasis.

关 键 词：结直肠癌 复发 转移 mSEPT9 CEA 

分 类 号：R735.34[医药卫生—肿瘤]